6 completed. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
Follow Hepatoma: new trials by email Literature Review of Hepatoma trials Research Report on Hepatoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Nivolumab, Relatlimab - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Completed | Bristol-Myers Squibb | 266 | 2021-02-04 | 2026-01-08 |
| Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma Regorafenib/Nivolumab - Carcinoma, Hepatocellular, Hepatoma | Phase 2 | Completed | Asan Medical Center | 42 | 2020-06-16 | 2022-12-06 |
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma TKM-080301 - Hepatocellular Carcinoma, Hepatoma | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 43 | 2014-06-01 | 2019-01-16 |
| Sorafenib and TRC105 in Hepatocellular Cancer TRC 105, Sorafenib - Hepatoma, Liver Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-02-11 | 2019-01-23 |
| Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma sorafenib, LC Bead-TACE - Hepatocellular Carcinoma, Hepatoma | Phase 2 | Completed | Yale University | 50 | 2009-02-01 | 2021-11-11 |
| Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma Bead Block microspheres, Bead + Dox Arm - Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 101 | 2007-11-01 | 2023-08-18 |
Carcinoma, Hepatocellular (6) · Liver Neoplasms (4) · Adenoma, Liver Cell (1) · Liver Neoplasms, Experimental (1)
Adenocarcinoma (6) · Carcinoma (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Liver Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Liver Neoplasms (2) · Adenoma (1) · Neoplasms, Experimental (1)
Nivolumab (2) · Sorafenib (2) · TKM-080301 (1) · carotuximab (1) · regorafenib (1) · relatlimab (1)
Arbutus Biopharma Corporation (1) · Asan Medical Center (1) · Bristol-Myers Squibb (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Yale University (1)
United States (4) · South Korea (3) · China (2) · Singapore (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · France (1) · Hong Kong (1) · Japan (1) · Mexico (1) · New Zealand (1)
Changhoon Yoo, MD, PhD (1) · Karen T Brown, MD (1) · Mark Kowalski, M.D., Ph.D. (1) · Tim F Greten, M.D. (1)
PMID 26834067, PMID 30598500, PMID 38374347
2018 (1)